Improvement Over the Years of Long-Term Survival in High-Risk Lymphoma Patients Treated with Hematopoietic Stem Cell Transplantation as Consolidation or Salvage Therapy

Calderón-Cabrera, Cristina; Márquez-Malaver, Francisco J.; Cruz-Vicente, Fátima de la; Falantes, F.; Carrillo, Estrella; Parody, Rocío; Montero, Isabel; Campos, José Alejandro González; Martino, M.L.; Carmona, María Teresa Padilla; Pérez‐Simón, José A.; Espigado, Ildefonso

doi:10.1016/j.transproceed.2013.11.007

Cited by 4 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contemporary registry analyses from the EBMT and the CIBMTR examining relapsed high grade lymphomas emphasize the curative potential of this procedure 32–33 , yet recognize the rarity of its use. Thus HCT is uncommonly applied despite recent reports of improved HCT outcomes for patients in the modern era 34–37 .…”

Section: Discussionmentioning

confidence: 99%

Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival

McClune¹,

Ahn²,

Wang³

et al. 2014

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Non-Hodgkin lymphomas (NHL) disproportionately affect older patients who uncommonly receive allogeneic hematopoietic cell transplantation (HCT). We analyzed CIBMTR data on 1248 patients ≥40 years receiving reduced-intensity conditioning (RIC) or non-myeloablative (NMA) HCT for aggressive (n=668) and indolent (n=580) NHL. Aggressive lymphoma was more frequent in the oldest cohort [(age 40–54) 49% vs. (55–64) 57% vs. (≥65) 67% p=0.0008]; fewer patients ≥65 had prior autografting [26% vs. 24% vs. 9%; p=0.002)]. Rates of relapse, acute and chronic GVHD and non-relapse mortality (NRM) at one year were similar [22%, 95% confidence interval (CI) 19–26%; 27%, 95% CI 23–31%; 34%, 95% CI 24–44%]. Progression-free (PFS) and overall (OS) survival at 3 years was slightly lower in older cohorts [OS:54%, 95% CI 50–58%; 40%, 95% CI 36–44%; 39%, 95% CI 28–50%; p<0.0001]. Multivariate analysis revealed no significant effect of age on acute or chronic GVHD or relapse. Age ≥55 years, Karnofsky performance status <80, and HLA-mismatch adversely impacted NRM, PFS, and OS. Disease status at HCT, but not histologic subtype, worsened NRM, relapse, PFS and OS. Even for patients ≥55 years, OS still approached 40% at 3 years suggesting HCT effects long-term remissions and remains underutilized in qualified older patients with NHL.

show abstract

Section: Discussionmentioning

confidence: 99%

Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival

McClune¹,

Ahn²,

Wang³

et al. 2014

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

show abstract

“…As the second line therapy, auto-HSCT has been established as a standard treatment for transplant eligible patients who have relapsed or refractory DLBCL, and it showed increased EFS and OS compared with conventional chemotherapy [26,27]. Lazarus et al [50] reported that compared to auto-HSCT patients, allo-HSCT patients had significantly worse 1-year probabilities of OS, PFS, and treatment-related mortality (TRM), but the differences were not significant at 3 or 5 years.…”

Section: Autologous and Allogeneic Hematopoietic Stem Cell Transplantmentioning

confidence: 99%

Treatment strategies for diffusive large B-cell lymphoma

Linling¹,

Lingqing²,

Gu³

et al. 2018

Oncol Res Rev

View full text Add to dashboard Cite

The treatment of diffusive large B-cell lymphoma (DLBCL) is generally based on multidrug chemotherapy, the association of cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) has become the standard therapy for DLBCL since the 1970s. The outcome of DLBCL has been substantially enhanced by the addition of the anti-CD20 monoclonal antibody rituximab. However, there is still some patients failed to the first-line treatment, those were considered as relapsed/ refractory DLBCL, and thus we need to adjust the dose or change the therapeutics. In addition, different treatment strategies should be stratified according to age, the International Prognostic Index (IPI), performance status, stage, prognostic score and immunohistochemical biomarkers. Besides, many novel drugs are under investigation in DLBCL patients, especially CAR-T regimen will have great prospects for development.

show abstract

Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma

Waibel

Gregory

Shortt³

et al. 2014

Current Opinion in Hematology

View full text Add to dashboard Cite

Treatment outcome with current combination chemotherapy is still poor for subsets of aggressive B-cell malignancies, and demands development of targeted therapeutic approaches. Advanced gene expression profiling and genomic sequencing have revealed a more detailed landscape of recurrent alterations, allowing a better subclassification of B-cell lymphomas and leukemias. Many alterations directly or indirectly lead to activation of survival signaling pathways and expression of key oncoproteins and prosurvival molecules, including Janus kinase-signal transducer and activator of transcription (JAK-STAT), phosphatidylinositol-3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR), avian myelocytomatosis viral oncogene homolog (MYC) and B-cell lymphoma 2 (BCLl-2). Small molecule inhibitors targeting these proteins and pathways are currently being tested in clinical trials and preclinically to improve chemotherapeutic regimes and treatment outcomes.

show abstract

Improvement Over the Years of Long-Term Survival in High-Risk Lymphoma Patients Treated with Hematopoietic Stem Cell Transplantation as Consolidation or Salvage Therapy

Cited by 4 publications

References 4 publications

Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival

Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival

Treatment strategies for diffusive large B-cell lymphoma

Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma

Contact Info

Product

Resources

About